~~<i id='1377A44887'><strike id='1377A44887'><tt id='1377A44887'><pre id='1377A44887'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：fashion 2025-10-01 15:39:50 - browse：1648

Biotech and life sciences investors continue to draw in new funds even as the biotech stock indexes reach new lows.

On Wednesday, VC firm Bioluminescence Ventures launched with $477 million to invest in biotech startups. The firm was founded by Kouki Harasaki, who was previously a partner at M12, Microsoft’s corporate venture group, and Andreessen Horowitz. He also has a track record at pharmaceutical companies like Novartis and Baxalta.

Bioluminescence joined at least four other firms — OrbiMed, Sofinnova Partners, Abingworth, and Revelation Partners — in announcing new pools of capital in the last two weeks. Together, they have raised $5.94 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Teladoc has a new CEO, but challenges remain the same

hotspot

knowledge

focus

knowledge

focus

AdobeWomenhavealwaysbeenunderrepresentedinmedicalresearch.Anewstudyrevealsthatnotmuchhaschanged,espe

WSS

Medical device trials still don't enroll enough women, study finds

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Cigna wins case to block Amy Bricker's move to CVS

Antivenom research: Lessons from HIV applied in search for universal antidote

Curing rare childhood diseases will falter unless Congress steps up

entertainment

fashion

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Teladoc has a new CEO, but challenges remain the same

State Dept. review finds Biden bears some blame for Afghanistan failures

Statins may not be needed by millions of people, study suggests

Duchenne breakthrough therapy leaves behind pioneering families

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Dobbs anniversary: the lost opportunity of abortion as health care

Stephen Quake on the Chan Zuckerberg quest to conquer disease

As demand for Covid shots wanes, Moderna seeks its next success

NIH study of ME/CFS points to clear biological hallmarks

knowledge

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Cigna wins case to block Amy Bricker's move to CVS

Dario to buy mental health app maker Twill in cash and stock deal

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Dario to buy mental health app maker Twill in cash and stock deal

Stephen Quake on the Chan Zuckerberg quest to conquer disease

knowledge

focus

knowledge

focus